tabrecta Speedy US approval for Novartis' Tabrecta By www.pharmatimes.com Published On :: Wed, 06 May 2020 22:47:33 +0100 The approval gives NSCLC patients whose tumours carry the MET exon 14 skipping mutation a new treatment option Full Article
tabrecta FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14 By www.pharmafile.com Published On :: Thu, 07 May 2020 11:35:49 +0000 The FDA has awarded marketing authorisation to Novartis for the Oral MET inhibitor Tabrecta for the first-line treatment of metastatic non-small cell lung cancer in patients whose tumors have a mutation that leads to MET exon 14 skipping (METex14), regardless of whether they have previously received any type of treatment. Full Article Incyte Novartis pharma Tabrecta Sales and Marketing
